Connection

Michael Zile to United States

Back to Details
This is a "connection" page, showing publications Michael Zile has written about United States.
Michael Zile
Connection Strength
0.643
United States
  1. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021 03 26; 21(1):155.
    View in: PubMed
    Score: 0.077
  2. Prognostic value of brain natriuretic peptide vs history of heart failure hospitalization in a large real-world population. Clin Cardiol. 2020 Dec; 43(12):1501-1510.
    View in: PubMed
    Score: 0.074
  3. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. Am Heart J. 2018 10; 204:139-150.
    View in: PubMed
    Score: 0.064
  4. Palliative Care for Advanced Heart Failure in a Department of Veterans Affairs Regional Hospice Program: Patient Selection, a Treatment Protocol, and Clinical Course. J Palliat Med. 2017 10; 20(10):1068-1073.
    View in: PubMed
    Score: 0.059
  5. Neuromodulation device therapy for treatment of hypertensive heart disease. Circ J. 2013; 77(6):1351-63.
    View in: PubMed
    Score: 0.045
  6. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.040
  7. Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure. J Am Coll Cardiol. 2007 Mar 06; 49(9):982-5.
    View in: PubMed
    Score: 0.029
  8. Peter C. Gazes: physician, teacher, scholar. Clin Cardiol. 2003 Mar; 26(3):158-9.
    View in: PubMed
    Score: 0.022
  9. Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. Am J Med. 2021 04; 134(4):e252-e263.
    View in: PubMed
    Score: 0.019
  10. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.016
  11. Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2018 Oct; 24(10):682-694.
    View in: PubMed
    Score: 0.016
  12. Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. Am Heart J. 2018 11; 205:1-11.
    View in: PubMed
    Score: 0.016
  13. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
    View in: PubMed
    Score: 0.016
  14. Heart Rate and Outcomes in Hospitalized?Patients With Heart Failure With Preserved Ejection?Fraction. J Am Coll Cardiol. 2017 Oct 10; 70(15):1861-1871.
    View in: PubMed
    Score: 0.015
  15. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017 May 30; 135(22):e1054-e1091.
    View in: PubMed
    Score: 0.015
  16. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016 Nov; 9(11).
    View in: PubMed
    Score: 0.014
  17. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan; 23(1):20-28.
    View in: PubMed
    Score: 0.014
  18. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016 Feb; 4(2):152-158.
    View in: PubMed
    Score: 0.013
  19. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep; 17(9):925-35.
    View in: PubMed
    Score: 0.013
  20. Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure. Circ Heart Fail. 2015 Jul; 8(4):733-40.
    View in: PubMed
    Score: 0.013
  21. Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST). Circ Heart Fail. 2015 Jan; 8(1):17-24.
    View in: PubMed
    Score: 0.012
  22. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation. 2015 Jan 06; 131(1):43-53.
    View in: PubMed
    Score: 0.012
  23. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014 Feb; 127(2):132-9.
    View in: PubMed
    Score: 0.011
  24. The Heart Failure Society of America in 2020: a vision for the future. J Card Fail. 2012 Feb; 18(2):90-3.
    View in: PubMed
    Score: 0.010
  25. Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation. 2005 Nov 15; 112(20):3107-14.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.